|
DCF -Bewertung der DCF
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Unicycive Therapeutics, Inc. (UNCY) Bundle
Bewerten Sie die finanzielle Aussichten von Unicycive Therapeutics, Inc. (unangemessen) wie ein Experte! Dieser (unangehige) DCF-Taschenrechner verfügt über vorgepopulierte Finanzdaten und bietet vollständige Flexibilität, um das Umsatzwachstum, WACC, Margen und andere wesentliche Annahmen zu ändern, um sich an Ihren Projektionen auszurichten.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | 1.0 | .7 | .6 | .6 | .5 | .5 | .5 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | -29.02 | -7.26 | -7.26 | -7.26 | -7.26 | -7.26 |
| EBITDA | -.1 | .0 | -9.0 | -18.0 | -30.2 | .1 | .1 | .1 | .1 | .1 |
| EBITDA, % | 100 | 100 | 100 | -1897.48 | -4470.81 | 20 | 20 | 20 | 20 | 20 |
| Depreciation | 2.0 | 2.0 | .0 | .0 | .3 | .4 | .4 | .4 | .3 | .3 |
| Depreciation, % | 100 | 100 | 100 | 0.73607 | 42.07 | 68.56 | 68.56 | 68.56 | 68.56 | 68.56 |
| EBIT | -2.0 | -2.0 | -9.0 | -18.1 | -30.5 | .1 | .1 | .1 | .1 | .1 |
| EBIT, % | 100 | 100 | 100 | -1898.21 | -4512.89 | 20 | 20 | 20 | 20 | 20 |
| Total Cash | .0 | .0 | 16.6 | .5 | 9.7 | .6 | .5 | .5 | .4 | .4 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | .4 | .3 | .3 | .3 | .3 |
| Account Receivables, % | 100 | 100 | 100 | 0 | 0 | 60 | 60 | 60 | 60 | 60 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .4 | .3 | .3 | .3 | .3 |
| Inventories, % | 100 | 100 | 100 | 0 | 0 | 60 | 60 | 60 | 60 | 60 |
| Accounts Payable | .3 | .2 | .7 | .8 | .8 | .6 | .6 | .5 | .5 | .5 |
| Accounts Payable, % | 100 | 100 | 100 | 88.96 | 121.63 | 97.79 | 97.79 | 97.79 | 97.79 | 97.79 |
| Capital Expenditure | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | -0.2103 | -1.78 | -0.39762 | -0.39762 | -0.39762 | -0.39762 | -0.39762 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -2.2 | -2.2 | -9.5 | -18.1 | -30.5 | .1 | .1 | .1 | .1 | .1 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | .1 | -.4 | -9.0 | -17.9 | -30.2 | -.4 | .5 | .5 | .4 | .4 |
| WACC, % | 14.31 | 14.31 | 14.31 | 14.31 | 14.31 | 14.31 | 14.31 | 14.31 | 14.31 | 14.31 |
| PV UFCF | ||||||||||
| SUM PV UFCF | .8 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 3 | |||||||||
| Present Terminal Value | 2 | |||||||||
| Enterprise Value | 3 | |||||||||
| Net Debt | -9 | |||||||||
| Equity Value | 11 | |||||||||
| Diluted Shares Outstanding, MM | 25 | |||||||||
| Equity Value Per Share | 0.47 |
What You Will Get
- Editable Excel Template: A fully customizable Excel-based DCF Calculator featuring pre-filled real UNCY financials.
- Real-World Data: Historical data and forward-looking estimates (as indicated in the yellow cells).
- Forecast Flexibility: Adjust forecast assumptions such as revenue growth, EBITDA %, and WACC.
- Automatic Calculations: Quickly see how your inputs affect Unicycive Therapeutics' valuation.
- Professional Tool: Designed for investors, CFOs, consultants, and financial analysts.
- User-Friendly Design: Organized for clarity and ease of use, complete with step-by-step instructions.
Key Features
- 🔍 Real-Life UNCY Financials: Pre-filled historical and projected data for Unicycive Therapeutics, Inc.
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate Unicycive’s intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Unicycive’s valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- Download the Template: Gain immediate access to the Excel-based UNCY DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and other variables.
- Instant Calculations: The model automatically recalculates Unicycive Therapeutics’ intrinsic value.
- Test Scenarios: Explore various assumptions to assess potential changes in valuation.
- Analyze and Decide: Leverage the results to inform your investment or financial strategies.
Why Choose This Calculator for Unicycive Therapeutics, Inc. (UNCY)?
- Accurate Data: Utilizes real Unicycive financials for dependable valuation outcomes.
- Customizable: Tailor essential parameters like growth rates, WACC, and tax rates to fit your forecasts.
- Time-Saving: Pre-defined calculations save you the hassle of building from the ground up.
- Professional-Grade Tool: Crafted for investors, analysts, and consultants in the biotech sector.
- User-Friendly: Designed with an intuitive interface and clear instructions for all users.
Who Should Use This Product?
- Professional Investors: Develop comprehensive valuation models for analyzing Unicycive Therapeutics, Inc. (UNCY) investments.
- Corporate Finance Teams: Evaluate valuation scenarios to shape strategic decisions for the company.
- Consultants and Advisors: Deliver precise valuation insights to clients interested in Unicycive Therapeutics, Inc. (UNCY).
- Students and Educators: Utilize real-world data to enhance learning in financial modeling related to biotech.
- Biotech Enthusiasts: Gain insights into how companies like Unicycive Therapeutics, Inc. (UNCY) are valued in the healthcare market.
What the Template Contains
- Comprehensive DCF Model: Editable template with detailed valuation calculations tailored for Unicycive Therapeutics, Inc. (UNCY).
- Real-World Data: Unicycive's historical and projected financials preloaded for thorough analysis.
- Customizable Parameters: Adjust WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for enhanced insights into performance.
- Key Ratios: Integrated analysis for profitability, efficiency, and leverage specific to Unicycive Therapeutics.
- Dashboard with Visual Outputs: Charts and tables designed for clear, actionable results regarding Unicycive's financial health.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.